The global market for Dysmenorrhea Treatment Market is projected to have a considerable CAGR of around 8.1% during the forecast period. Dysmenorrhea, also known as menstrual cramps, is cramping or throbbing pains in the lower abdomen. Dysmenorrhea affects the majority of women right before and throughout their menstrual cycles. Dysmenorrhea is of two types, that’s is primary and secondary dysmenorrhea. Prostaglandin-induced uterine contractions cause primary dysmenorrhea and pelvic pain caused by (secondary to) a disorder or disease known as secondary dysmenorrhea. Dysmenorrhea causes complications such as endometriosis that results in fertility problems, increasing the risk of a fertilized egg implanting outside of the uterus (ectopic pregnancy), and pelvic inflammatory disease can scar fallopian tubes. Changing lifestyle, environmental changes, and food habits have had a significant impact on human bodies. This has led to an increase in the incidence of dysmenorrhea among women. This is a major factor driving the global dysmenorrhea treatment market. According to the study published in the International Journal of Gynecology & Obstetrics, dysmenorrhea affects more than 80% of women in the reproductive age, and it is the most frequent gynecological condition globally.

Impact of COVID-19 on Dysmenorrhea treatment Market 

COVID-19 had a negative impact on the dysmenorrhea treatment market. COVID-19 may have a significant impact on both the healthcare system and chronic pain patients. As a result, delaying or discontinuing therapy for chronic pain patients will have negative consequences, and strong pain evaluations must be administered to triage patients appropriately. However, COVID-19 infection is likely to affect a women's menstruation due to stress, and COVID-19 symptoms are also likely to be influenced by menstruation. Therefore, this factor is creating an opportunity for market growth during the COVID-19 pandemic. 

Segmental Outlook  

The global dysmenorrhea treatment market is segmented based on treatment types, and type. Based on the treatment types, the market is further classified as non-steroidal anti-inflammatory drugs (NSAIDs), and, hormonal therapy. Further, based on the type the market is classified into primary dysmenorrhea, and secondary dysmenorrhea. 

Global Dysmenorrhea Treatment Market Share by Treatment Types, 2021 (%)

The NSAIDs is considered as dominating segment in the global dysmenorrhea treatment market. 

Among treatment types, the non-steroidal anti-inflammatory drugs segment holds a significant market share in the dysmenorrhea treatment market. It is expected to show a similar trend over the forecast period due to the highly effective relieving pain, lower cost, and easy availability of products. Some of the US Food and Drug Administration (FDA) approved NSAIDs for the treatment of dysmenorrhea are diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen. According to the Women's Health Concern and the British Menopause Society, over 80% of dysmenorrhea women will have period pain at some point during their lifetime. During menstruation, most women suffer some discomfort, especially on the first day. However, the discomfort is severe enough to disturb the lives of 5% to 10% of women. Moreover, the prevalence of diseases such as endometriosis, which is the leading cause of secondary dysmenorrhea, is also globally is accelerating the demand for non-steroidal anti-inflammatory drugs segment

Regional Outlook 

Geographically, the global Dysmenorrhea Treatment Market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (India, China, Japan, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). North America is likely to hold a significant market share in the global dysmenorrhea treatment market due to the growing prevalence and incidence of dysmenorrhea and rising awareness of dysmenorrhea among females in this region. According to a study published in the Indian Journal of Research, incapacitating dysmenorrhea costs the United States roughly 2 billion dollars or 600 million working hours each year. Furthermore, women who attend classes or work during their dysmenorrhea have been reported to have decreased work productivity or scores.

Global Dysmenorrhea treatment Market Growth, by region 2022-2028

Asia-Pacific to hold a considerable CAGR in the global dysmenorrhea treatment Market

Geographically, Asia-Pacific is projected to hold a significant CAGR global Dysmenorrhea treatment Market. The growth is attributed to rising incidences that have led to increased health awareness among women to tackle dysmenorrhea. As a result, treatments and medicines that help to relieve pain throughout the menstrual cycle have been developed by the region’s major players, and this has also contributed to the market's expansion in Asia-Pacific. Some of the major players in the region include Teva Pharmaceutical Industries Ltd, Pfizer Inc, Sanofi, Janssen Pharmaceuticals, Inc, Sun Pharmaceutical Industries Ltd. among other domestic and Global players.

Market Players Outlook

The key players in the dysmenorrhea treatment market contribute significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi among others. These market players adopt various strategies such as product launches, partnerships, collaborations, mergers, and acquisitions to sustain a strong position in the market. In July 2019, Teva Pharmaceuticals Inc. has announced the purchase of three buildings on West Chester's Brandywine Parkway. These freshly purchased facilities, along with Teva Pharmaceuticals' existing buildings in the same business park, have completed the North America Research & Development facility project. The facility will primarily focus on biologics and will continue to research in order to prepare for future expansion.

The Report Covers

• Market value data analysis of 2021 and forecast to 2028.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global dysmenorrhea treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market entry and market expansion strategies.
• Competitive strategies by identifying 'who-stands-where in the market.